Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance
Evotec will apply its proprietary and integrated fragment-based drug discovery platform, EVOlution(TM) to the programme. The key benefit of this platform for the selection of target-specific strategies is its versatility, combining biochemical and biophysical techniques including nuclear magnetic resonance (NMR), surface plasmon resonance (SPR) and X-ray crystallography. Within this collaboration, EVOlution(TM) will be used to investigate protein-protein interactions on targets selected by Shionogi.
Dr Mario Polywka, COO of Evotec stated: "We are extremely pleased that Shionogi has decided to undertake these projects with Evotec. Our proprietary fragment-based drug discovery platform has shown that it adds significant value to our partner's programmes and we look forward to supporting Shionogi in finding novel treatments for inflammation and infectious diseases."
No financial details are disclosed.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.